Evaluation of the preventive effect of sublingual immunotherapy for pediatric bronchial asthma.

OBJECTIVE

This study aimed to determine the effectiveness of sublingual immunotherapy (SLIT) in preventing the exacerbation of asthma.

METHODS

This retrospective study investigated the changes in the rate of continuous steroid inhalation introduced over three years due to SLIT in 328 patients aged 5-15 years who were diagnosed with allergic rhinitis between January 1, 2018, and December 31, 2019. These patients were not initially prescribed with continuous steroid inhalation. SLIT and symptomatic treatment groups were compared over 3 years using chi-square and Fisher's exact tests, controlling for age with multiple regression analysis. The SLIT subgroups and factors contributing to asthma exacerbation were examined as secondary endpoints.

RESULTS

The study comprised 151 patients in the SLIT group and 177 patients in the symptomatic treatment group, with higher average age and IgE levels in the SLIT group. High continuation rates for SLIT were observed over 3 years. Asthma exacerbation within 3 years was notably lower in the SLIT group, particularly in the cedar-only and combined SLIT groups. Multiple regression analysis confirmed the duration of SLIT as a significant factor in preventing asthma exacerbation. Additionally, Fisher's exact test supported these findings.

CONCLUSION

This study demonstrated the effectiveness of SLIT in reducing the exacerbation of asthma in children with allergic rhinitis. SLIT was associated with lower rates of asthma exacerbation over a three-year period compared to symptomatic treatment.